Skip to main
TCRX
TCRX logo

TScan Therapeutics (TCRX) Stock Forecast & Price Target

TScan Therapeutics (TCRX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

TScan Therapeutics Inc. demonstrates a significant potential for growth due to its promising clinical results in liquid tumor therapies, particularly with its TSC-100 and TSC-101 candidates showing a notable 70% improvement in event-free survival (EFS) and a remarkably low relapse rate of 8% compared to 33% in the control arm. The company's strategic development of multiplex TCR-T therapies for solid tumors is supported by the recent FDA clearance for an additional immunotherapy candidate, facilitating broader treatment options for patients, especially in non-small cell lung cancer. TScan is expected to capitalize on its innovative approach and strong early efficacy data, positioning itself for pivotal studies aimed at expanding its market presence in both hematologic malignancies and solid tumor sectors.

Bears say

TScan Therapeutics Inc reported a significantly increased net loss of $35.8 million, or ($0.30 per share), in the fourth quarter of 2024, compared to a loss of $19.6 million, or ($0.21 per share), in the same quarter of the previous year. There are concerns that the company's upcoming clinical updates may reveal multiple patient relapses in its TSC-100 and TSC-101 therapies, leading to a reduction in its probability of success in treating hematological malignancies to 45%. Additional worries persist regarding TScan's potential inability to develop further successful clinical candidates beyond its current programs, contributing to a negative outlook on the company's stock valuation and performance.

TScan Therapeutics (TCRX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TScan Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TScan Therapeutics (TCRX) Forecast

Analysts have given TScan Therapeutics (TCRX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, TScan Therapeutics (TCRX) has a Strong Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TScan Therapeutics (TCRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.